Literature DB >> 19692138

The evasive promise of antiangiogenic therapy.

Jean-François Dufour1.   

Abstract

Year:  2009        PMID： 19692138     DOI： 10.1016/j.jhep.2009.07.006

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  2 in total

1.  YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.

Authors:  Ting Sun; Wenhao Mao; Hui Peng; Qi Wang; Lin Jiao
Journal:  Cell Oncol (Dordr)       Date:  2021-03-03       Impact factor: 6.730

2.  Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.

Authors:  P-F Zhang; K-S Li; Y-H Shen; P-T Gao; Z-R Dong; J-B Cai; C Zhang; X-Y Huang; M-X Tian; Z-Q Hu; D-M Gao; J Fan; A-W Ke; G-M Shi
Journal:  Cell Death Dis       Date:  2016-04-21       Impact factor: 8.469
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.